Efficacy and safety of Daratumumab, Bortezomib, Melphalan, and Prednisone (D-VMP) versus Bortezomib, Melphalan, and Prednisone (VMP) in Chinese patients with newly diagnosed Multiple Myeloma: OCTANS

被引：0

作者：

Fu, Weijun ^{[1
]}

Huang, Honghui ^{[2
]}

Li, Wei ^{[3
]}

An, Gang ^{[4
]}

Cai, Zhen ^{[5
]}

Jin, Jie ^{[5
]}

Wang, Yafei ^{[6
]}

Chim, Chor Sang ^{[7
]}

Qi, Ming ^{[8
]}

Wang, Jianping ^{[9
]}

Song, Yang ^{[10
]}

Jia, Bin ^{[11
]}

Yang, Xue ^{[11
]}

Liu, Wenyu ^{[10
]}

Li, Yunan ^{[12
]}

Zhang, Renyi ^{[13
]}

Hou, Jian ^{[14
]}

Wang, Jianxiang ^{[4
]}

机构：

[1] Shanghai Changzheng Hosp, Shanghai, Peoples R China

[2] Shanghai Jiao Tong Univ, Renji Hosp, Dept Hematol, Sch Med, Shanghai, Peoples R China

[3] First Hosp Jilin Univ, Dept Hematol, Oncol Ctr, Changchun, Peoples R China

[4] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, Tianjin, Peoples R China

[5] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Hangzhou, Zhejiang, Peoples R China

[6] Tianjin Canc Hosp, Tianjin, Peoples R China

[7] Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Peoples R China

[8] Janssen Res & Dev LLC, Spring House, PA USA

[9] Janssen Res & Dev LLC, Raritan, NJ USA

[10] Janssen Res & Dev LLC, Beijing, Peoples R China

[11] Janssen Res & Dev LLC, Shanghai, Peoples R China

[12] Xian Janssen Pharmaceut Ltd, Med Affairs, Beijing, Peoples R China

[13] Xian Janssen Pharmaceut Ltd, Med Affairs, Shanghai, Peoples R China

[14] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Hematol, Shanghai, Peoples R China

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2021年 / 21卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-163

引用

页码：S125 / S125

页数：1

共 50 条

[1] Daratumumab, Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) Alone in Transplant-Ineligible Asian Patients with Newly Diagnosed Multiple Myeloma: Final Analysis of the Phase 3 Octans Study
Fu, Weijun
Bang, Soo-Mee
Huang, Honghui
Kim, Kihyun
Li, Wei
An, Gang
Lee, Je-Jung
Cai, Zhen
Jin, Jie
Wang, Yafei
Chim, Chor Sang
Carson, Robin
Liu, Rui
Wang, Lingling
Zhao, Man
Chen, Xi
Cui, Canchan
Hou, Jian
Wang, Jianxiang
BLOOD, 2023, 142
[2] Comparative Efficacy and Safety of Daratumumab in Combination with Bortezomib, Melphalan, and Prednisone (D-VMP) in Alcyone Versus Bortezomib, Melphalan, and Prednisone (VMP) in Vista in Newly Diagnosed Multiple Myeloma (NDMM) Patients Using Propensity Score Matching (PSM)
Cavo, Michele
Dimopoulos, Meletios A.
San-Miguel, Jesus F.
Mateos, Maria-Victoria
Jakubowiak, Andrzej
Deraedt, William
Lam, Annette
Kampfenkel, Tobias
Qi, Ming
He, Jianming
BLOOD, 2018, 132
[3] Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible for Transplant (ALCYONE)
Mateos, Maria-Victoria
Dimopoulos, Meletios A.
Cavo, Michele
Suzuki, Kenshi
Jakubowiak, Andrzej J.
Knop, Stefan
Doyen, Chantal
Lucio, Paulo
Nagy, Zsolt
Kaplan, Polina
Pour, Ludek
Cook, Mark
Grosicki, Sebastian
Crepaldi, Andre H.
Liberati, Anna Marina
Campbell, Philip
Shelekhova, Tatiana
Yoon, Sung-Soo
Iosava, Genadi
Fujisaki, Tomoaki
Garg, Mamta
Chiu, Christopher
Wang, Jianping
Carson, Robin
Crist, Wendy
Deraedt, William
Nguyen, Marie
Qi, Ming
San-Miguel, Jesus F.
BLOOD, 2017, 130
[4] DARATUMUMAB PLUS BORTEZOMIB, MELPHALAN, AND PREDNISONE (D-VMP) VERSUS BORTEZOMIB, MELPHALAN, AND PREDNISONE (VMP) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS (PTS) INELIGIBLE FOR TRANSPLANT: A PHASE 3 RANDOMIZED STUDY (ALCYONE)
Mateos, M., V
Dimopoulos, M. A.
Cavo, M.
Suzuki, K.
Jakubowiak, A.
Knop, S.
Doyen, C.
Lucio, P.
Nagy, Z.
Kaplan, P.
Pou
Cook, M.
Grosicki, S.
Crepaldi, A.
Liberati, A. M.
Campbell, P.
Shelekhova, T.
Yoon, S. S.
Iosava, G.
Fujisaki, T.
Garg, M.
Chiu, C.
Wang, J.
Carson, R.
Crist, W.
Deraedt, W.
Nguyen, H.
Qi, M.
San-Miguel, J.
HAEMATOLOGICA, 2018, 103 : 22 - 22
[5] Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Alcyone Study
Mateos, Maria-Victoria
San-Miguel, Jesus
Cavo, Michele
Creixenti, Joan Blade
Suzuki, Kenshi
Jakubowiak, Andrzej
Knop, Stefan
Doyen, Chantal
Lucio, Paulo
Nagy, Zsolt
Pour, Ludek
Grosicki, Sebastian
Crepaldi, Andre H.
Liberati, Anna Marina
Campbell, Philip
Shelekhova, Tatiana
Yoon, Sung-Soo
Iosava, Genadi
Fujisaki, Tomoaki
Garg, Mamta
Pei, Huiling
Krevvata, Maria
Carson, Robin
Borgsten, Fredrik
Dimopoulos, Meletios A.
BLOOD, 2022, 140 : 10157 - 10159
[6] Daratumumab, Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in TransplantIneligible Patients with Newly Diagnosed Multiple Myeloma: Pooled Analysis of Octans and Alcyone
Hou, Jian
Fu, Weijun
Bang, Soo-Mee
Huang, Honghui
Kim, Kihyun
Li, Wei
An, Gang
Lee, Je-Jung
Cai, Zhen
Jin, Jie
Wang, Yafei
Chim, C. S.
Rodriguez-Otero, Paula
Dimopoulos, Meletios A.
Fujisaki, Tomoaki
Lee, Jae Hoon
Wroblewski, Susan
Carson, Robin
Qi, Ming
Wang, Jianping
Song, Yang
Bin Jia
Yang, Xue
Liu, Wenyu
Li, Yunan
Zhang, Renyi
Wang, Jianxiang
BLOOD, 2021, 138
[7] One-Year Update of a Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Patients (Pts) with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): Alcyone
Dimopoulos, Meletios A.
Mateos, Maria-Victoria
Cavo, Michele
Suzuki, Kenshi
Jakubowiak, Andrzej
Knop, Stefan
Doyen, Chantal
Lucio, Paulo
Nagy, Zsolt
Kaplan, Polina
Pour, Ludek
Cook, Mark
Grosicki, Sebastian
Crepaldi, Andre H.
Liberati, Anna Marina
Campbell, Philip
Shelekhova, Tatiana
Yoon, Sung-Soo
Iosava, Genadi
Fujisaki, Tomoaki
Garg, Mamta
Chiu, Christopher
Wang, Jianping
Kudva, Anupa
Kobos, Rachel
Wroblewski, Susan
Qi, Ming
San-Miguel, Jesus F.
Blade, Joan
BLOOD, 2018, 132
[8] A Prospective, Randomized, Phase III Study of Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) Versus Bortezomib, Melphalan and Prednisone (VMP) in Elderly Newly Diagnosed Myeloma Patients
Palumbo, Antonio
Bringhen, Sara
Rossi, Davide
Magarotto, Valeria
Di Raimondo, Francesco
Ria, Roberto
Offidani, Massimo
Nozzoli, Chiara
Patriarca, Francesca
Callea, Vincenzo
Benevolo, Giulia
Marasca, Roberto
Guglielmelli, Tommasina
Rizzo, Manuela
Grasso, Mariella
Petrucci, Maria Teresa
Omede, Paola
Gaidano, Gianluca
Boccadoro, Mario
BLOOD, 2008, 112 (11) : 243 - 243
[9] BORTEZOMIB, MELPHALAN, PREDNISONE AND THALIDOMIDE (VMPT) VERSUS BORTEZOMIB, MELPHALAN AND PREDNISONE (VMP) IN ELDERLY NEWLY DIAGNOSED MYELOMA PATIENTS: A PROSPECTIVE, RANDOMIZED, PHASE III STUDY
Palumbo, A.
Bringhen, S.
Rossi, D.
Ria, R.
Berretta, S.
Offidani, M.
Patriarca, F.
Nozzoli, C.
Levi, A.
Guglielmelli, T.
Benevolo, G.
Callea, V.
Liberati, A. M.
Crippa, C.
Di Renzo, N.
Catalano, L.
De Sabbata, G.
Rizzi, R.
Feo, C.
Mazza, R.
Farina, G.
Spadano, A.
Pisani, F.
Podda, L.
Aitoro, G.
Magarotto, V.
Astolfi, M.
Di Raimondo, F.
Gaidano, G.
Boccadoro, M.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 190 - 191
[10] Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study
Morabito, Fortunato
Bringhen, Sara
Larocca, Alessandra
Wijermans, Pierre
Victoria Mateos, Maria
Gimsing, Peter
Mazzone, Carla
Gottardi, Daniela
Omede, Paola
Zweegman, Sonja
Jose Lahuerta, Juan
Zambello, Renato
Musto, Pellegrino
Magarotto, Valeria
Schaafsma, Martijn
Oriol, Albert
Juliusson, Gunnar
Cerrato, Chiara
Catalano, Lucio
Gentile, Massimo
Isabel Turel, Ana
Liberati, Anna Marina
Cavalli, Maide
Rossi, Davide
Passera, Roberto
Rosso, Stefano
Beksac, Meral
Cavo, Michele
Waage, Anders
San Miguel, Jesus
Boccadoro, Mario
Sonneveld, Pieter
Palumbo, Antonio
Offidani, Massimo
AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (04) : 355 - 362

← 1 2 3 4 5 →